MacGregor, Kylie A., Robertson, Mark J., Young, Kelly A., von Kleist, Lisa, Stahlschmidt, Wiebke, Whiting, Ainslie, Chau, Ngoc , Robinson, Phillip J., Haucke, Volker, and McCluskey, Adam (2014) Development of 1,8-naphthalimides as clathrin inhibitors. Journal of Medicinal Chemistry, 57 (1). pp. 131-143.

PDF (Published Version) - Published Version Restricted to Repository staff only

 

26

4

Abstract

We reported the first small molecule inhibitors of the interaction between the clathrin N-terminal domain (TD) and endocyctic accessory proteins (i.e., clathrin inhibition1). Initial screening of a ∼17 000 small molecule ChemBioNet library identified 1. Screening of an existing in-house propriety library identified four substituted 1,8-napthalimides as ∼80–120 µM clathrin inhibitors. Focused library development gave 3-sulfo-N-(4-aminobenzyl)-1,8-naphthalimide, potassium salt (18, IC50 ≈ 18 µM). A second library targeting the 4-aminobenzyl moiety was developed, and four analogues displayed comparable activity (26, 27, 28, 34 with IC50 values of 22, 16, 15, and 15 μM respectively) with a further four (24, 25, 32, 33) more active than 18 with IC50 values of 10, 6.9, 12, and 10 μM, respectively. Docking studies rationalized the structure–activity relationship (SAR) with the biological data. 3-Sulfo-N-benzyl-1,8-naphthalimide, potassium salt (25) with an IC50 ≈ 6.9 µM, is the most potent clathrin terminal domain–amphiphysin inhibitor reported to date.

Actions (Repository Staff Only)

Item Control Page